Skip to main content

Galmed Pharmaceuticals Ltd.

EOCN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001595353

No open-market purchases or sales by Galmed Pharmaceuticals Ltd. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $85.9K in total; no superinvestor holds it.

Q2 2024 vs. Q1 2024

How the institutions holding Galmed Pharmaceuticals Ltd. changed between Q1 2024 and Q2 2024.

All holders in Q2 2024All holders in Q1 2024

13F holders of EOCN: Q1 2024 compared with Q2 2024
MeasureQ1 2024Q2 2024Change
Holders13130
Shares172.7K396.9K+224.3K (+129.9%)
Value$57.6K$112.9K+$55.3K (+96.1%)

New holders (1)

Institutions that held Galmed Pharmaceuticals Ltd. at the end of Q2 2024 but not at the end of Q1 2024.

Institutions new to EOCN in Q2 2024
InstitutionSharesValue% of portfolio
Susquehanna International Group, LLP11,625$3.33K0.00%

Sold out (1)

Institutions that held Galmed Pharmaceuticals Ltd. at the end of Q1 2024 and filed for Q2 2024 without it.

Institutions that sold out of EOCN in Q2 2024
InstitutionShares, Q1 2024Value, Q1 2024
Two Sigma Advisers, LP22,267$7.71K